Teleflex
Builds medical devices for vascular access, interventional, and surgical procedures.
Something off on this page? Send us feedback.
Profile
Develops medical devices for vascular access, interventional, and surgical markets. An acquisition added coronary and peripheral intervention capability, while announced sales of Acute Care, Interventional Urology, and OEM businesses remain pending closing.
Develops medical devices for vascular access, interventional, and surgical markets. Its acquisition of BIOTRONIK’s Vascular Intervention business added coronary and peripheral intervention capability.
The workforce spans the United States and 38 other countries, giving the company an international operating footprint. Its portfolio has been built through acquisitions and divestitures, including the earlier shift away from aerospace and commercial operations.
The business is in a further reset: announced sales of its Acute Care, Interventional Urology, and OEM businesses had not closed as of the latest context update. The stated remaining focus is vascular access, interventional, and surgical markets.
Company facts
Categories
Key statistics
Year to date +14.1% · Average volume (30d) 565.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Needham | Reiterate | Buy | $159 | $170 | |
| Aug 11, 2026 | UBS | Reiterate | Neutral | $145 | $158 | |
| Aug 10, 2026 | Truist Financial | Target | $135 | $150 | ||
| Jul 31, 2026 | Needham | Reiterate | Buy | $147 | $159 | |
| Jul 28, 2026 | UBS | Initiate | Neutral | $145 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $1.28 | $1.76 | +37.5% | $559.6M | $570.3M | +1.9% | +1.54% |
| May 7, 2026Q1 FY26 | $1.21 | $1.39 | +14.9% | $536.9M | $548.3M | +2.1% | +1.05% |
| Feb 26, 2026Q4 FY25 | $3.73 | $1.93 | −48.3% | $919.3M | $569.0M | −38.1% | +2.55% |
| Nov 6, 2025Q3 FY25 | $3.38 | $3.67 | +8.6% | $915.0M | $913.0M | −0.2% | +0.82% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $700.7M | $780.9M | $913.0M | $569.0M | $548.3M | $570.3M | |
| Gross profit | $389.4M | $431.1M | $451.6M | $307.4M | $307.4M | $331.7M | |
| Operating income | $125.6M | $155.3M | −$29.7M | $36.3M | $20.2M | $60.3M | |
| Net income | $95.0M | $122.6M | −$408.9M | −$714.3M | −$8.2M | $102.0M | |
| Diluted EPS | $2.07 | $2.77 | −$9.24 | −$16.15 | −$0.18 | $2.28 | |
| Gross margin | 55.6% | 55.2% | 49.5% | 54.0% | 56.1% | 58.2% | |
| Operating margin | 17.9% | 19.9% | -3.3% | 6.4% | 3.7% | 10.6% |
Fiscal years (4-quarter sums)FY21 $2.81B · FY22 $2.79B · FY23 $2.97B · FY24 $3.05B · FY25 $2.96B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $300.2M · Total debt $2.87B · Total assets $6.79B · Shareholders' equity $2.90B
Dividends
Raised for 38 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 14, 2026 | Aug 14 | Sep 30 | $0.34 | |
| May 22, 2026 | May 25 | Jun 30 | $0.34 | |
| Mar 6, 2026 | Mar 6 | Mar 31 | $0.34 | |
| Nov 14, 2025 | Nov 14 | Dec 15 | $0.34 | |
| Aug 15, 2025 | Aug 15 | Sep 15 | $0.34 | |
| May 20, 2025 | May 20 | Jun 16 | $0.34 | |
| Mar 7, 2025 | Mar 7 | Mar 17 | $0.34 | |
| Nov 15, 2024 | Nov 15 | Dec 16 | $0.34 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 44.27M · Float 43.91M · 99.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.43M | 12.27% | 13F | Aug 7, 2026 |
| Jupiter Topco LLC | 4.34M | 9.81% | 13F | Aug 14, 2026 |
| Janus Henderson Group PLC | 4.15M | 9.40% | 13G | Aug 14, 2025 |
| T. Rowe Price Investment Management, Inc. | 3.19M | 7.22% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.42M | 5.46% | 13F | Aug 13, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- BD
Broad vascular-access and peripheral-intervention hospital portfolio
- ICU Medical
Vascular-access consumables for hospital infusion and access care
- Boston Scientific
Coronary and peripheral vascular technologies for catheter-lab procedures
- Abbott
Large vascular portfolio for coronary and peripheral artery disease
- Medtronic
Scaled coronary and peripheral vascular medical-technology portfolio
- Merit Medical Systems
Vascular-access and cardiac/peripheral-intervention device specialist
- Johnson & Johnson
Surgical instrumentation, stapling and wound-closure product platform
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Teleflex | $139.67 | −0.01% | $6.18B | — | 15.2 | 2.4 | −27.0% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| ICU Medical | $175.10 | +0.01% | $4.38B | 148.4 | 19.7 | 2.0 | −0.2% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Merit Medical Systems | $90.49 | +0.10% | $5.40B | 37.4 | 20.7 | 3.4 | +9.5% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 36.2 | 19.4 | 3.3 | +7.5% |